2052-2053 / 2351
Regimens
N ORR
(%)
Median survival
(months)
Cisplatin/5-FU
vs
Carboplatin/5-FU
vs
Methotrexate
277
32%
21%
10%
6.6
5
5.6
*Cisplatin/pemetrexed*
vs
Cisplatin
795
12.1%
8.%
7.3*
6.3
p= 0.082
Jacobs et al JCO 2002, Clavel et al Ann Oncol 1994,
Forastiere et al JCO 1992, Urba et Cancer 2012
*
ECOG 0-1:
OS (8.4 vs 6.7 months; p=0.026)
Oropharyngeal:
OS (9.9 vs 6.1 months; p=0.002)
Randomized trials mono vs polychemotherapy